Share-based Payment Arrangement, Expense of Omega Therapeutics, Inc. from 30 Jun 2020 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Omega Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2024.
  • Omega Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $1,723,000, a 24% decline year-over-year.
  • Omega Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $8,480,000, a 3.7% decline year-over-year.
  • Omega Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,793,000, a 13% increase from 2022.
  • Omega Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,753,000, a 143% increase from 2021.
  • Omega Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3,184,000, a 400% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Omega Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $8,480,000 $1,723,000 -$557,000 -24% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $9,037,000 $1,213,000 -$965,000 -44% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $10,002,000 $3,431,000 +$1,209,000 +54% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2024 2024 Q1
Q4 2023 $8,793,000 $2,113,000 -$9,000 -0.42% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2024 2023 FY
Q3 2023 $8,802,000 $2,280,000 +$307,000 +16% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $8,495,000 $2,178,000 +$124,000 +6% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $8,371,000 $2,222,000 +$618,000 +39% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $7,753,000 $2,122,000 +$940,000 +80% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $6,813,000 $1,973,000 +$850,000 +76% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,963,000 $2,054,000 +$1,369,000 +200% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $4,594,000 $1,604,000 +$1,410,000 +727% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $3,184,000 $1,182,000 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $1,123,000 +$894,000 +390% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $685,000 +$578,000 +540% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $194,000 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q3 2020 $229,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $107,000 01 Apr 2020 30 Jun 2020 10-Q 10 Sep 2021 2021 Q2

Omega Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $8,793,000 +$1,040,000 +13% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2024 2023 FY
2022 $7,753,000 +$4,569,000 +143% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $3,184,000 +$2,547,000 +400% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
2020 $637,000 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.